Hongisto Mari, Lassus Johan, Tarvasmäki Tuukka, Sionis Alessandro, Sans-Rosello Jordi, Tolppanen Heli, Kataja Anu, Jäntti Toni, Sabell Tuija, Lindholm Matias Greve, Banaszewski Marek, Silva Cardoso Jose, Parissis John, Di Somma Salvatore, Carubelli Valentina, Jurkko Raija, Masip Josep, Harjola Veli-Pekka
Division of Emergency Medicine, Department of Emergency Medicine and Services, Helsinki University Hospital, PO Box 900, Helsinki, 00029 HUS, Finland.
Cardiology, University of Helsinki and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
ESC Heart Fail. 2021 Apr;8(2):1398-1407. doi: 10.1002/ehf2.13224. Epub 2021 Jan 31.
This study aimed to assess the utility of contemporary clinical risk scores and explore the ability of two biomarkers [growth differentiation factor-15 (GDF-15) and soluble ST2 (sST2)] to improve risk prediction in elderly patients with cardiogenic shock.
Patients (n = 219) from the multicentre CardShock study were grouped according to age (elderly ≥75 years and younger). Characteristics, management, and outcome between the groups were compared. The ability of the CardShock risk score and the IABP-SHOCK II score to predict in-hospital mortality and the additional value of GDF-15 and sST2 to improve risk prediction in the elderly was evaluated. The elderly constituted 26% of the patients (n = 56), with a higher proportion of women (41% vs. 21%, P < 0.05) and more co-morbidities compared with the younger. The primary aetiology of shock in the elderly was acute coronary syndrome (84%), with high rates of percutaneous coronary intervention (87%). Compared with the younger, the elderly had higher in-hospital mortality (46% vs. 33%; P = 0.08), but 1 year post-discharge survival was excellent in both age groups (90% in the elderly vs. 88% in the younger). In the elderly, the risk prediction models demonstrated an area under the curve of 0.75 for the CardShock risk score and 0.71 for the IABP-SHOCK II score. Incorporating GDF-15 and sST2 improved discrimination for both risk scores with areas under the curve ranging from 0.78 to 0.84.
Elderly patients with cardiogenic shock have higher in-hospital mortality compared with the younger, but post-discharge outcomes are similar. Contemporary risk scores proved useful for early mortality risk prediction also in the elderly, and risk stratification could be further improved with biomarkers such as GDF-15 or sST2.
本研究旨在评估当代临床风险评分的效用,并探讨两种生物标志物[生长分化因子-15(GDF-15)和可溶性ST2(sST2)]改善心源性休克老年患者风险预测的能力。
多中心CardShock研究中的患者(n = 219)按年龄分组(老年≥75岁和年轻组)。比较两组之间的特征、治疗及结局。评估CardShock风险评分和IABP-SHOCK II评分预测院内死亡率的能力,以及GDF-15和sST2改善老年患者风险预测的附加价值。老年患者占患者总数的26%(n = 56),女性比例更高(41%对21%,P < 0.05),且与年轻患者相比合并症更多。老年患者休克的主要病因是急性冠状动脉综合征(84%),经皮冠状动脉介入治疗率较高(87%)。与年轻患者相比,老年患者院内死亡率更高(46%对33%;P = 0.08)但两组出院后1年生存率均良好(老年组90%,年轻组88%)。在老年患者中,风险预测模型显示CardShock风险评分的曲线下面积为0.75,IABP-SHOCK II评分为0.71。纳入GDF-15和sST2可改善两种风险评分的辨别能力,曲线下面积范围为0.78至0.84。
与年轻患者相比,心源性休克老年患者院内死亡率更高,但出院后结局相似。当代风险评分对老年患者早期死亡风险预测也有用,且生物标志物如GDF-15或sST2可进一步改善风险分层。